Please Note: New Treatments Have Emerged Since this Original Post

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

Dr. Jason Brown discusses emerging research on the effect of microbiomes and genomics on immunotherapy in bladder cancer.

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

What is the role for the neuroprotective agent memantine in patients receiving whole brain radiation therapy for brain metastases? Dr. Vivek Mehta reviews current practices to minimize risk of cognitive problems. Please feel free to offer comments and raise questions in our Discussion Forums

Radiation Oncologist Dr. Vivek Mehta reviews the concept of using whole brain radiation for multiple brain metastases, including how it is delivered and risks and benefits of this strategy. Please feel free to offer comments and raise questions in our Discussion Forums. TranscriptI see a number of

Radiation therapy can be very helpful in treating painful bone metastases or those at risk for causing a fracture due to compromise of bone strength. Dr. Vivek Mehta reviews the basics of this approach. Please feel free to offer comments and raise questions in our Discussion Forums

Dr. Nasser Hanna, Indiana University Health, addresses the issue of prophylactic cranial irradiation (PCI) in locally advanced NSCLC.

Dr. David Harpole, Duke University Medical Center, describes how he assists patients with the surgical decision-making process.

TranscriptOne of the important points about patients with advanced lung cancer is that 30-40% of patients will develop bone metastases. I think it’s important to recognize this is not bone cancer, this is lung cancer that’s moved to the bone, and in 30-40% of patients at some point who have advanced

UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.